July 27, 2021

Portolano Cavallo announces the appointment of Elisa Stefanini as partner

Portolano Cavallo is pleased to announce that attorney Elisa Stefanini, who has been with the firm since 2017, has been promoted from counsel to partner. The total number of partners now rises to fourteen — seven women and seven men.

Elisa Stefanini assists Life Sciences and Healthcare players in regulatory matters such as market accessclinical trials, and promotion of drugs, medical devices, and food supplements to the public and to healthcare professionals. She also has extensive experience on digital health and telemedicine projects and all other aspects of digitalization of the Life Sciences and Healthcare sector.

Francesco Portolano, partner at Portolano Cavallo says, “In 2016 we added Life Sciences & Healthcare to our historical Digital, Media, Technology focus. Elisa’s appointment to partner is a major milestone marking the great success achieved in this area over the last five years. Thanks to Elisa and our Life Sciences group, we now represent some of the largest Italian and foreign pharmaceutical multinationals, medical device manufacturers, healthcare service providers, investors, and startups, and many others in the sector.”

Since 2019, Elisa has been included in the Legal 500 EMEA as a “Next Generation Partner” for Healthcare and Life Sciences and she is also included in Who’s Who Legal as an expert in Life Sciences (“National Leader” in the Italy guide) and Life Sciences – Regulatory (“Global Leader”).

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
July 19, 2022
Guidelines for the implementation of the Electronic Health Record (EHR) to ensure dissemination, uniformity and accessibility of the EHR at national level now published in the Official Gazet...
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
Search by...
Search
Follow us on
Follow us on